Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

FDA advisory committee to review Amylyx ALS drug again

The FDA will reconvene its Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) to discuss Amylyx’s ALS drug candidate later this year, the company announced this week.

The advisory board had previously met in March to discuss the New Drug Application (NDA) for AMX0035. After the FDA determined that additional analyses from clinical studies constitute major amendments to the application, the drug will be evaluated again for the treatment of amyotrophic lateral sclerosis in September of this year.

AMX0035 is an oral-fixed dose medication currently approved with conditions under the brand name Albrioza to treat ALS in Canada. The drug works by combining sodium phenylbutyrate and taurursodiol which are believed to reduce neuronal cell death by mitigating stress and dysfunction of crucial organelles, or the cell’s organs.

“We are pleased that the members of the advisory panel will review additional analyses from our clinical studies, including recently published analyses, supporting the previously reported functional and overall survival benefit for AMX0035,” said Tammy Sarnelli, Global Head of Regulatory Affairs of Amylyx. “As we have heard from the ALS community, there is a crucial need for new and effective treatments in ALS, and our team will continue to work around the clock to advance treatments for ALS in the U.S.”

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025